Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp is positioned for a positive financial outlook, primarily due to strong growth projections for its MACI product, which is expected to see volume increases in the low-to-mid teens, along with annual average selling price (ASP) growth of 300 to 500 basis points. Projections for fiscal year 2026 estimate MACI's top-line revenue growth in the high teens to low 20s range, aligning with overall market expectations of approximately 21.2% year-over-year growth. Additionally, the anticipated revenue for the fourth quarter reflects a notable increase of 26% quarter-over-quarter, indicating solid momentum heading into the new fiscal year.

Bears say

Vericel Corp's outlook is negatively impacted by lowered revenue expectations for its MACI product in fiscal years 2026 and 2027, with a reduction of approximately 200 basis points. Additionally, there are significant risks related to slower uptake of the MACI Arthro, potential declines in burn care sales, and disruptions associated with the expansion of the sales force. If Vericel fails to meet top-line expectations in upcoming quarters, it is anticipated that the company's shares could decline to historical low valuation levels.

Vericel (VCEL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.